Suppr超能文献

人泡沫病毒载体表达的小干扰RNA对乙型肝炎病毒复制的有效抑制作用

Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.

作者信息

Sun Yan, Li Zhi, Li Lijun, Li Jing, Liu Xiaobo, Li Wenxin

机构信息

College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710062, P.R. China.

出版信息

Int J Mol Med. 2007 Apr;19(4):705-11.

Abstract

RNA interference (RNAi) mediated by double- stranded small interfering RNA (siRNA) is a novel mechanism of sequence-specific, post-transcriptional gene silencing. There has been much research into the use of RNAi for the treatment of human diseases. Many viruses, including hepatitis B virus (HBV), are susceptible to inhibition by this mechanism. However, for RNAi to be efficacious therapeutically, effective RNAi targeting sequences and a suitable delivery system are required. In this study, we employed a polymerase chain reaction (PCR)-based siRNA expression strategy to rapidly screen for effective siRNA sequences. Two effective siRNAs sequences (designated as S2 and X1) which reduced the HBV RNA by >90% were identified. For delivering the siRNAs, they were cloned into a human foamy virus (HFV)-based vector to generate single siRNA expression vectors HFVU6-siS2, HFVU6-siX1 and a dual siRNA expression vector HFVU6-siSX. The results showed that these siRNA vectors effectively inhibited multiple HBV gene expression and viral DNA replication based on ELISA and quantitative PCR analysis. HFVU6-siSX which simultaneously expressed two siRNAs that targeted the S and X genes of HBV is the most potent inhibitor of HBV replication. In addition, the repression of HBV RNA and DNA was stable for up to 3 months post-transduction as determined by RT-PCR and Southern blotting. Collectively, the PCR-based siRNA expression strategy provides a rapid and easy approach for testing candidate anti-HBV siRNA sequences and for cloning selected siRNA expression cassettes into a vector. RNAi based on the HFV vector was able to achieve effective, long-term inhibition of HBV gene expression and viral DNA replication. The combination of the two techniques may provide a powerful tool in the treatment of viral infection.

摘要

由双链小干扰RNA(siRNA)介导的RNA干扰(RNAi)是一种序列特异性的转录后基因沉默新机制。关于将RNAi用于治疗人类疾病已有很多研究。包括乙型肝炎病毒(HBV)在内的许多病毒都易受这种机制的抑制。然而,要使RNAi在治疗上有效,需要有效的RNAi靶向序列和合适的递送系统。在本研究中,我们采用基于聚合酶链反应(PCR)的siRNA表达策略来快速筛选有效的siRNA序列。鉴定出了两个能将HBV RNA降低>90%的有效siRNA序列(命名为S2和X1)。为了递送这些siRNA,将它们克隆到基于人泡沫病毒(HFV)的载体中,以产生单个siRNA表达载体HFVU6-siS2、HFVU6-siX1和双siRNA表达载体HFVU6-siSX。基于酶联免疫吸附测定(ELISA)和定量PCR分析的结果表明,这些siRNA载体有效地抑制了多种HBV基因表达和病毒DNA复制。同时表达靶向HBV S基因和X基因的两个siRNA的HFVU6-siSX是最有效的HBV复制抑制剂。此外,通过逆转录PCR(RT-PCR)和Southern印迹法测定,转导后长达3个月,HBV RNA和DNA的抑制作用是稳定的。总的来说,基于PCR的siRNA表达策略为测试候选抗HBV siRNA序列以及将选定的siRNA表达盒克隆到载体中提供了一种快速简便的方法。基于HFV载体的RNAi能够实现对HBV基因表达和病毒DNA复制的有效长期抑制。这两种技术的结合可能为治疗病毒感染提供一个强大的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验